Vancouver, British Columbia – September 13, 2011 – Sirona Biochem Corp. (TSX-V: SBM) (the “Company”), a biotechnology company specializing in carbohydrate chemistry technology, including the development of diabetes and obesity therapeutics, cosmeceuticals and biological ingredients, is pleased to announce its appointment of Dr. Jocelyne Legoedec to the position of Lead Project Biologist at its subsidiary company, TFChem, in France.
Dr. Jocelyne Legoedec will be based at Sirona Biochem’s French subsidiary, TFChem, and will contribute with Dr. Bertrand Plouvier to leading, directing and managing the biological assessment and complete characterization of drug candidates and cosmetic and biological agents from discovery through to preclinical proof of concept.
About Dr. Jocelyne Legoedec
Jocelyne Legoedec is specialized in cellular biology and received her PhD degree in 1997 from the University of Rouen, France. During her doctoral fellowship at INSERM laboratory, she proved the biosynthesis and activation of the complement proteins by human myoblasts from primary cultures and cell lines. Her post doctoral research includes studying the role of the complement system in muscular physiology and pathology. Prior to joining TFChem, Dr. Legoedec was Diagnostic Product Manager at Biohit plc. in Finland, where she managed the clinical evaluation for a new diagnostic test to diagnose early stages of H.pylori infection and ulcer or gastric cancer. This role also involved the marketing and commercialization of the new diagnostic test in public and private biological analysis laboratories. Previously, Dr. Legoedec was a Research Engineer at the University Hospital of Rouen, where she managed a clinical study on autoimmune pathologies and rheumatoid arthritis involving a 500 patient cohort. This project took place with an industrial partner in order to develop new diagnostic tests for detection of specific autoantibodies. Dr. Legoedec received her Bachelor of Science from the University of Technologies of CAEN in France, followed by her Masters in Applied Biology and Physiology and PhD in Cellular Biology, both from the University of Rouen, France.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company specializing in carbohydrate chemistry. We are applying a proprietary chemistry technique towards the development of diabetes and cancer therapeutics, cosmeceuticals and biological ingredients. Sirona Biochem aims to develop enhanced carbohydrate-based molecules by improving their pharmaceutical properties. Our lead product, a sodium glucose transporter (SGLT) inhibitor for Type 2 diabetes, recently achieved positive preclinical results. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Julie Jang
Director, Communications
Sirona Biochem Corp.
Phone: 604.282.6065
Email: jjang@sironabiochem.com
———————————————
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.